Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1

被引:19
作者
Cruz, LJ
Iglesias, E
Aguilar, JC
Cabrales, A
Reyes, O
Andreu, D
机构
[1] Univ Barcelona, Inst Rec Biomed Barcelona, E-08028 Barcelona, Spain
[2] Ctr Ingn Genet & Biotecnol, Cubanacan, Habana, Cuba
[3] Univ Pompeu Fabra, Dept Ciencias Expt & Salut, E-08003 Barcelona, Spain
关键词
D O I
10.1021/bc049944u
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The critical role that antibody responses to the V3 loop epitope play in human immunodeficiency virus type 1 (HIV-1) neutralization has caused this peptide to be used in many HIV-1 vaccine candidates. To enhance cross-reactivity toward several V3 sequences, a database of 50 peptides of the V3 region from HIV-1 subtype A was used to design both a consensus peptide and a combinatorial peptide (mixotope) library representative of these sequences. The two immunogens (consensus and mixotope) were incorporated into multiple antigen peptide (MAP) constructions, conjugated to a recombinant surface antigen from hepatitis B virus (HbsAg) carrier protein, and inoculated to mice in combination with a C4 (CD4-binding) peptide MAP construction, also conjugated to HBsAg. The respective responses and cross-reactivity to several V3 loop sequences of both types of immunogens were compared. Mice inoculated with the V3 consensus-MAP-HBsAg + C4-MAP-HBsAg mixture elicited higher antibody responses than those given the V3 mixotope-MAP-HBsAg + C4-MAP-HBsAg mixture. In addition, pooled serum from the first group of immunogens analyzed at dilution 1:100 had higher cross-reactivity against V3 peptides on cellulose membranes than those from mice given the combinatorial immunogen. Fine epitope mapping of both consensus and C4 peptide by the spot synthesis technique showed that sera of the first group strongly recognized both sequences in their entirety, whereas mice immunized with the mixotope library recognized only the N-terminal region of V3. These results seem to suggest that the V3 consensus peptide is superior to the combinatorial strategy in inducing potent and cross-reactive responses to HIV.
引用
收藏
页码:1110 / 1117
页数:8
相关论文
共 35 条
[1]   Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1 [J].
Aguilar, A ;
Carrazana, Y ;
Duarte, CA .
BIOMOLECULAR ENGINEERING, 2001, 18 (03) :117-124
[2]  
Barouch D H, 2000, Dev Biol (Basel), V104, P85
[3]   Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers [J].
Birx, DL ;
Loomis-Price, LD ;
Aronson, N ;
Brundage, J ;
Davis, C ;
Deyton, L ;
Garner, R ;
Gordin, F ;
Henry, D ;
Holloway, W ;
Kerkering, T ;
Luskin-Hawk, R ;
McNeil, J ;
Michael, N ;
Pierce, PF ;
Poretz, D ;
Ratto-Kim, S ;
Renzullo, P ;
Ruiz, N ;
Sitz, K ;
Smith, G ;
Tacket, C ;
Thompson, M ;
Tramont, E ;
Yangco, B ;
Yarrish, R ;
Redfield, RR .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :881-889
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
CARDONNIER A, 1989, NATURE, V340, P571
[6]  
Cruz LJ, 2000, J PEPT SCI, V6, P217, DOI 10.1002/(SICI)1099-1387(200005)6:5<217::AID-PSC242>3.3.CO
[7]  
2-L
[8]   A comparative study of different presentation strategies for an HIV peptide immunogen [J].
Cruz, LJ ;
Iglesias, E ;
Aguilar, JC ;
González, LJ ;
Reyes, O ;
Albericio, F ;
Andreu, D .
BIOCONJUGATE CHEMISTRY, 2004, 15 (01) :112-120
[9]   Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins [J].
Cruz, LJ ;
Iglesias, E ;
Aguilar, JC ;
Quintana, D ;
Garay, HE ;
Duarte, C ;
Reyes, O .
JOURNAL OF PEPTIDE SCIENCE, 2001, 7 (09) :511-518
[10]   A NOVEL CARBODIIMIDE COUPLING METHOD FOR SYNTHETIC PEPTIDES - ENHANCED ANTIPEPTIDE ANTIBODY-RESPONSES [J].
DEEN, C ;
CLAASSEN, E ;
GERRITSE, K ;
ZEGERS, ND ;
BOERSMA, WJA .
JOURNAL OF IMMUNOLOGICAL METHODS, 1990, 129 (01) :119-125